Guggenheim initiates Faeth Therapeutics at Buy; $70 price target
Benzinga reports Guggenheim initiated Faeth Therapeutics (FTH) with a Buy rating and a $70.00/share price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.